Next-generation site-specific cysteine-based antibody–drug-conjugates (ADCs) broaden therapeutic index by precise drug-antibody attachments. However, manufacturing such ADCs for clinical validation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results